EntreMed to Present at BioPartnering Europe Conference
ROCKVILLE, Md., Oct. 10 /PRNewswire-FirstCall/ — EntreMed, Inc. a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, announced today that Thomas H. Bliss, Jr., EntreMed’s Senior Vice President, Corporate and Business Development, will present a Company overview at the 16th Annual BioPartnering Europe Conference, which is being held October 12-14, 2008 in London, United Kingdom. Mr. Bliss’ presentation is scheduled for Monday, October 13, 2008 at 12:15 p.m. (local time).
(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )
Mr. Bliss will provide an overview of the Company’s clinical-stage programs, with particular emphasis on ENMD-2076 and 2ME2 for rheumatoid arthritis. ENMD-2076, an orally-active, Aurora/angiogenesis inhibitor for the treatment of cancer, is in a multi-center Phase 1b dose-escalation study in patients with solid tumors. Panzem(R) (2ME2), an orally-active small molecule angiogenesis inhibitor with disease modifying properties for the treatment of rheumatoid arthritis (RA), has completed a Phase 1 clinical trial in healthy volunteers. EntreMed is actively marketing ENMD-2076 and 2ME2 for RA to prospective pharmaceutical and biotech company partners as a means to accelerate the development and commercialization of these novel drug candidates.
Mr. Bliss’s presentation will not be web cast; however, a copy of his presentation will be available through the Company’s web site at http://www.entremed.com/.
EntreMed, Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. MKC-1, an oral cell-cycle regulator with activity against the mTOR pathway, is currently in multiple Phase 2 clinical trials for cancer. ENMD-1198, a novel antimitotic agent, and ENMD-2076, a selective kinase inhibitor, are in Phase 1 studies in advanced cancers. The Company also has an approved IND application for Panzem(R) in rheumatoid arthritis. EntreMed’s goal is to develop and commercialize new compounds based on the Company’s expertise in angiogenesis, cell cycle regulation, cell signaling and inflammation — processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the Company’s web site at http://www.entremed.com/ and in various filings with the Securities and Exchange Commission.
Forward Looking Statements
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance (including the timing of royalty revenues and future R&D expenditures), strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in Securities and Exchange Commission filings under “Risk Factors,” including risks relating to the need for additional capital and the uncertainty of additional funding; variations in actual sales of Thalomid(R), risks associated with the Company’s product candidates; the early-stage products under development; results in preclinical models are not necessarily indicative of clinical results, uncertainties relating to preclinical and clinical trials; success in the clinical development of any products; dependence on third parties; future capital needs; and risks relating to the commercialization, if any, of the Company’s proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks).
CONTACT: Ginny Dunn Associate Director Corporate Communications & Investor Relations EntreMed, Inc. 240-864-2643
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGOAP Archive: http://photoarchive.ap.org/PRN Photo Desk, firstname.lastname@example.org
CONTACT: Ginny Dunn, Associate Director of Corporate Communications &Investor Relations of EntreMed, Inc., +1-240-864-2643
Web site: http://www.entremed.com/